Suppr超能文献

采用亲和诱饵和化学报告物策略鉴定拉考沙胺结合蛋白:14-3-3 ζ。

Identification of a lacosamide binding protein using an affinity bait and chemical reporter strategy: 14-3-3 ζ.

机构信息

Division of Medicinal Chemistry and Natural Products, UNC Eshelman School of Pharmacy, University of North Carolina, Chapel Hill, North Carolina 27599-7568, USA.

出版信息

J Am Chem Soc. 2011 Jul 27;133(29):11320-30. doi: 10.1021/ja2034156. Epub 2011 Jul 6.

Abstract

We have advanced a useful strategy to elucidate binding partners of ligands (drugs) with modest binding affinity. Key to this strategy is attaching to the ligand an affinity bait (AB) and a chemical reporter (CR) group, where the AB irreversibly attaches the ligand to the receptor upon binding and the CR group is employed for receptor detection and isolation. We have tested this AB&CR strategy using lacosamide ((R)-1), a low-molecular-weight antiepileptic drug. We demonstrate that using a (R)-lacosamide AB&CR agent ((R)-2) 14-3-3 ζ in rodent brain soluble lysates is preferentially adducted, adduction is stereospecific with respect to the AB&CR agent, and adduction depends upon the presence of endogenous levels of the small molecule metabolite xanthine. Substitution of lacosamide AB agent ((R)-5) for (R)-2 led to the identification of the 14-3-3 ζ adduction site (K120) by mass spectrometry. Competition experiments using increasing amounts of (R)-1 in the presence of (R)-2 demonstrated that (R)-1 binds at or near the (R)-2 modification site on 14-3-3 ζ. Structure-activity studies of xanthine derivatives provided information concerning the likely binding interaction between this metabolite and recombinant 14-3-3 ζ. Documentation of the 14-3-3 ζ-xanthine interaction was obtained with isothermal calorimetry using xanthine and the xanthine analogue 1,7-dimethylxanthine.

摘要

我们提出了一种有用的策略来阐明具有适度结合亲和力的配体(药物)的结合伙伴。该策略的关键是将亲和诱饵(AB)和化学报告基团(CR)连接到配体上,其中 AB 在结合时不可逆地将配体连接到受体上,而 CR 基团用于受体检测和分离。我们已经使用拉科酰胺((R)-1)这种低分子量抗癫痫药物测试了这种 AB&CR 策略。我们证明,在啮齿动物脑可溶性裂解物中使用(R)-拉科酰胺 AB&CR 试剂((R)-2)14-3-3 ζ,优先进行加合物形成,加合物形成相对于 AB&CR 试剂具有立体特异性,并且加合物形成取决于内源性小分子代谢物黄嘌呤的存在水平。用拉科酰胺 AB 试剂((R)-5)替代(R)-2 导致通过质谱鉴定 14-3-3 ζ 加合物位点(K120)。使用(R)-2 存在下逐渐增加(R)-1 的竞争实验表明,(R)-1 结合在 14-3-3 ζ 上的(R)-2 修饰位点上或附近。黄嘌呤衍生物的结构活性研究提供了有关该代谢物与重组 14-3-3 ζ 之间可能的结合相互作用的信息。使用黄嘌呤和黄嘌呤类似物 1,7-二甲基黄嘌呤通过等温量热法获得了 14-3-3 ζ-黄嘌呤相互作用的文档记录。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/51e1/3148493/4fd1b3f61cad/nihms309961f1.jpg

相似文献

引用本文的文献

本文引用的文献

5
Nucleoside map of the human central nervous system.人类中枢神经系统的核苷图谱。
Neurochem Res. 2010 Mar;35(3):452-64. doi: 10.1007/s11064-009-0080-z. Epub 2009 Oct 24.
9
Lacosamide.拉科酰胺
Nat Rev Drug Discov. 2008 Dec;7(12):973-4. doi: 10.1038/nrd2764.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验